Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Roundtable Discussion: Treatment Goals for HCC and Tolerability of Frontline Regimens
December 27th 2022During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.
Read More
Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCC
November 9th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
Read More
Health Derailed in Houston After Authorities Confirm Liver Cancer Cluster
October 31st 2022Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.
Read More
Interpreting Results From New and Previous Trials of Lenvatinib in HCC
October 26th 2022During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Read More
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular Carcinoma
October 26th 2022Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Read More
Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC Treatment
October 14th 2022Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.
Read More
Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC
October 14th 2022The phase 1b Study 116/KEYNOTE-524 trial of lenvatinib and pembrolizumab revealed the RAS gene signature to possibly be associated with progression-free survival in unresectable hepatocellular carcinoma.
Read More
Frontline Tislelizumab Shows Non-Inferior OS vs Sorafenib in Unresectable HCC
September 11th 2022At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
Read More
Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.
Read More
Roundtable Discussion: Abou-Alfa Evaluates Choice of Therapy for HCC Based on Patient Factors
August 25th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.
Read More
Pembrolizumab Plus Lenvatinib Misses Primary End Points in Unresectable HCC
August 5th 2022While treatment with pembrolizumab and lenvatinib vs lenvatinib alone seemed to have survival benefit in patients with unresectable hepatocellular carcinoma, the primary end points of the trial were missed.
Read More